Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
The largest domestic drug maker Ranbaxy Laboratories is planning to introduce two of Daiichi Sankyos discovered products in
Olmesartan medoxomil is already available in more than 50 countries worldwide. Additionally, the two companies plan to promote Prasugrel, an anti-platelet, co-developed by Daiichi Sankyo and Eli Lilly, in the Latin American market. Prasugrel will be co-promoted by Lilly's affiliate in
With an estimated population of 107 million people,
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1652.10 |
Dr. Reddys Lab | 1095.15 |
Cipla | 1416.30 |
Lupin | 1921.30 |
Zydus Lifesciences | 844.60 |
View more.. |